David Gaiero
Financieel Directeur/CFO bij CYTEIR THERAPEUTICS, INC.
Vermogen: 308 197 $ op 31-03-2024
Actieve functies van David Gaiero
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-12-2020 | - |
| Treasurer | 16-03-2022 | - | |
| IMUNON, INC. | Comptroller/Controller/Auditor | 01-06-2024 | - |
| Financieel Directeur/CFO | 01-06-2024 | - | |
| Monomoy Advisors LLC | Corporate Officer/Principal | - | - |
Loopbaan van David Gaiero
Eerdere bekende functies van David Gaiero
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| WAVE LIFE SCIENCES LTD. | Comptroller/Controller/Auditor | 01-07-2017 | 04-12-2020 |
| Financieel Directeur/CFO | 09-01-2020 | 04-12-2020 | |
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Comptroller/Controller/Auditor | 01-01-2015 | 01-01-2017 |
Opleiding van David Gaiero
| University of Massachusetts | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
| Singapore | 2 |
Operationeel
| Comptroller/Controller/Auditor | 3 |
| Director of Finance/CFO | 3 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| IMUNON, INC. | Health Technology |
| WAVE LIFE SCIENCES LTD. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
| Monomoy Advisors LLC |
- Beurs
- Insiders
- David Gaiero
- Ervaring
